YOU GOT THIS

LUTATHERA®
(lutetium Lu 177 dotatate)
injection, for intravenous use

20,000+ patients chose LUTATHERA to treat their NETs—join in their strength

Preparing for your LUTATHERA journey:
Reminders for before, during, and after treatment

Actor portrayal.

NETs, neuroendocrine tumors.

What is LUTATHERA?

LUTATHERA® (lutetium Lu 177 dotatate) is a prescription medicine used to treat adults and children aged 12 years and older with a type of cancer known as gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that are positive for the hormone receptor somatostatin, including GEP-NETs in the foregut, midgut, and hindgut.

IMPORTANT SAFETY INFORMATION

What are some important things to know about the safety of LUTATHERA?

LUTATHERA is associated with some serious safety considerations and, in some cases, these may require your health care provider to adjust or stop your treatment.

Please see additional Important Safety Information throughout and full Prescribing Information for LUTATHERA.

NOVARTIS

What should I expect before each dose of LUTATHERA?

4 WEEKS OR MORE BEFORE TREATMENT

- Your doctor will stop your long-acting somatostatin analogue (SSA) treatment until your first LUTATHERA dose
- You may receive a short-acting SSA to help with symptoms before you start LUTATHERA

24 HOURS OR MORE BEFORE TREATMENT

- Your doctor will stop short-acting SSA treatment at least 24 hours before each infusion

LUTATHERA is given in 4 intravenous (IV) treatments, once every 8 weeks



- Between **4 to 24 hours after each dose** of LUTATHERA, you'll get an intramuscular (IM) injection of **long-acting SSA**
- After your last dose of LUTATHERA, you may continue receiving long-acting SSA every 4 weeks for **up to 18 months**

IMPORTANT SAFETY INFORMATION (continued)

What are some important things to know about the safety of LUTATHERA? (continued)

You should always follow your health care provider's instructions. Safety considerations include:

Please see additional Important Safety Information throughout and full Prescribing Information for LUTATHERA.

LUTATHERA® (lutetium Lu 177 dotatate) injection, for intravenous use

Reminders before starting treatment

Make appointments for blood work

- You may need blood work and other tests to evaluate your kidneys, liver, and blood
- Pregnancy status will be verified before starting LUTATHERA because it has the potential to cause fetal harm

Have a plan for contraception

- If you are a female who is able to get pregnant, be prepared to use effective contraception during treatment with LUTATHERA and for 7 months after the last dose
- If you are a male with a female partner who is able to get pregnant, be prepared to use effective contraception during treatment with LUTATHERA and for 4 months after the last dose

Prepare for infusion day

- Confirm the date and time of your LUTATHERA treatment. Make travel arrangements if your treatment center is not local
- Bring a water bottle for hydration
- Check with your treatment center on what else to bring for treatment

Actor portrayal.

IMPORTANT SAFETY INFORMATION (continued)

- **Radiation exposure:** Treatment with LUTATHERA will expose you to radiation, which can contribute to your long-term radiation exposure.

Please see additional Important Safety Information throughout and full Prescribing Information for LUTATHERA.

LUTATHERA®
(lutetium Lu 177 dotatate)
injection, for intravenous use

What should I expect on infusion day?

BEFORE RECEIVING YOUR INFUSION AT THE TREATMENT CENTER

- You will be given a medicine to help with any nausea and vomiting that you may experience
- Thirty minutes before you are given LUTATHERA, you will start an amino acid infusion. This will help protect your kidneys

GETTING YOUR LUTATHERA INFUSION

- The total infusion time is ~4 to 5 hours
  - LUTATHERA infusion takes 30 to 40 minutes
  - You will continue the amino acid infusion for at least 3 hours after the LUTATHERA infusion to protect your kidneys
  - Your care team will monitor you throughout the day

Reminder during treatment

Keep a record of your infusion details

- Bring a LUTATHERA treatment card (can be found on **LUTATHERA.com/resources**) with you to record the details of each appointment. You can also bring these with you when you travel
- Inform other health care professionals about your LUTATHERA treatment and the guidance to reduce radiation exposure



Your care team will be with you every step of the way. Always check with them if you have questions about laboratory tests or your next LUTATHERA dose

IMPORTANT SAFETY INFORMATION (continued)

- **Radiation exposure (continued):** Overall radiation exposure is associated with an increased risk for cancer.

Please see additional Important Safety Information throughout and full Prescribing Information for LUTATHERA.

LUTATHERA® (lutetium Lu 177 dotatate) injection, for intravenous use

What does follow-up after my infusion look like?

4 TO 24 HOURS AFTER LUTATHERA INFUSION

- Your care team will tell you when and where you will receive a long-acting SSA

LAB TESTS

- Your care team will do regular blood work and other tests to see how you are doing on treatment
- These tests can tell them if you are having side effects and will help them give you the care you need

Reminders after treatment

Keep up with your LUTATHERA treatments

- After each treatment, confirm the date and time of your next appointment
- It is important to receive all your LUTATHERA treatments at their scheduled times. If you are unable to go to a treatment, reschedule as soon as possible

*After your last dose of LUTATHERA, you may continue receiving long-acting SSA every 4 weeks for **up to 18 months***

IMPORTANT SAFETY INFORMATION (continued)

- **Radiation exposure (continued):** The radiation will be detectable in your urine for up to 30 days following administration of the drug. It is important to minimize radiation exposure to household contacts consistent with good radiation safety practices as advised by your health care provider.

Please see additional Important Safety Information throughout and full Prescribing Information for LUTATHERA.

LUTATHERA®
(lutetium Lu 177 dotatate)
injection, for intravenous use

Help reduce radiation exposure after treatment

Help reduce radiation exposure to those around you

Stay hydrated

- Drink plenty of fluids the day before, the day of, and the day after treatment to help get rid of any extra radiation

Shower daily

- Shower daily after treatment

Maintain distance after treatment and separate belongings*

- Separate your belongings
- Stay at least 3 feet from your loved ones (and pets)
- Sleep in a separate bedroom and avoid sex for 3 days

Stay seated on the toilet

- Use the toilet in a seated position and flush twice for at least 3 days after your LUTATHERA dose
- Your loved ones should use gloves when providing bathroom assistance

Separate your clothing/laundry

- At the treatment center, change into hospital scrubs/gowns
- At home, use separate towels and washcloths and wash your clothing separately for at least 3 days after treatment

Throw away waste

- Flush or throw away items that have been exposed to bodily fluids
- Separate contaminated waste from household waste

*Ask your doctor or radiation technologist for more information.

IMPORTANT SAFETY INFORMATION (continued)

- **Bone marrow problems:** Treatment with LUTATHERA increases the risk of myelosuppression, a condition in which bone marrow activity is decreased, resulting in a drop in blood cell counts.

Please see additional Important Safety Information throughout and full Prescribing Information for LUTATHERA.

LUTATHERA®
(lutetium Lu 177 dotatate)
injection, for intravenous use

Watch for side effects

The most common and most serious side effects of LUTATHERA include:

- Decreased blood cell counts
- Vomiting
- Increased blood glucose
- Increased liver enzymes
- Nausea
- Decreased blood potassium levels

Treatment centers will have their own guidance for radiation safety. Always follow your care team's instructions and ask them any questions you may have



Actor portrayal.

IMPORTANT SAFETY INFORMATION (continued)

- **Bone marrow problems (continued):** You may experience blood-related side effects such as low red blood cells (anemia), low numbers of cells that are responsible for blood clotting (thrombocytopenia), and low numbers of white blood cells (neutropenia).

Please see additional Important Safety Information throughout and full Prescribing Information for LUTATHERA.

LUTATHERA®
(lutetium Lu 177 dotatate)
injection, for intravenous use

What is LUTATHERA?

LUTATHERA® (lutetium Lu 177 dotatate) is a prescription medicine used to treat adults and children aged 12 years and older with a type of cancer known as gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that are positive for the hormone receptor somatostatin, including GEP-NETs in the foregut, midgut, and hindgut.

IMPORTANT SAFETY INFORMATION

What are some important things to know about the safety of LUTATHERA?

LUTATHERA is associated with some serious safety considerations and, in some cases, these may require your health care provider to adjust or stop your treatment. You should always follow your health care provider's instructions. Safety considerations include:

- **Radiation exposure:** Treatment with LUTATHERA will expose you to radiation, which can contribute to your long-term radiation exposure. Overall radiation exposure is associated with an increased risk for cancer. The radiation will be detectable in your urine for up to 30 days following administration of the drug. It is important to minimize radiation exposure to household contacts consistent with good radiation safety practices as advised by your health care provider.
- **Bone marrow problems:** Treatment with LUTATHERA increases the risk of myelosuppression, a condition in which bone marrow activity is decreased, resulting in a drop in blood cell counts. You may experience blood-related side effects such as low red blood cells (anemia), low numbers of cells that are responsible for blood clotting (thrombocytopenia), and low numbers of white blood cells (neutropenia). Speak with your health care provider if you experience any signs or symptoms of infection, fever, chills, dizziness, shortness of breath, or increased bleeding or bruising. Your health care provider may need to adjust or stop your treatment accordingly.
- **Secondary bone marrow and blood cancers:** Other serious conditions that you may develop as a direct result of treatment with LUTATHERA include blood and bone marrow disorders known as secondary myelodysplastic syndrome and cancer known as acute leukemia. Your health care provider will routinely check your blood cell counts and tell you if they are too low or too high.
- **Kidney problems:** Treatment with LUTATHERA will expose your kidneys to radiation and may impair their ability to work as normal. You may be at an increased risk for kidney problems after LUTATHERA treatment if you already have kidney impairment before treatment. In some cases, patients have experienced kidney failure after treatment with LUTATHERA. Your health care provider will provide you with an amino acid solution before, during, and after LUTATHERA to help protect your kidneys. You should stay well hydrated before, on the day of, and on the day after your treatment. You should urinate frequently before, on the day of, and on the day after administration of LUTATHERA. Your doctor will monitor your kidney function and may withhold, reduce, or stop your LUTATHERA treatment accordingly.
- **Liver problems:** In clinical studies of LUTATHERA, less than 1% of patients were reported to have tumor bleeding (hemorrhage), swelling (edema), or tissue damage (necrosis) to the liver. If you have tumors in your liver, you may be more likely to experience these side effects. Tell your health care provider right away if you have any of these signs and symptoms of liver problems:

- **Liver problems (continued):** yellowing of the skin or the whites of the eyes (jaundice), unusual darkening of the urine, unusual tiredness, right upper stomach area (abdomen) pain, confusion, and/or swelling of the stomach area (abdomen). Your health care provider will monitor your liver using blood tests and may need to withhold, reduce, or stop your LUTATHERA treatment accordingly.
- **Allergic reactions:** Allergic reactions have occurred in people who were treated with LUTATHERA. Notify your health care provider if you develop symptoms of an allergic reaction. Seek emergency help right away for any serious allergic reactions. Symptoms may include trouble breathing or swallowing; raised bumps (hives); rash or itching; and swelling of the face, lips, tongue, throat, or arms.
- **Hormonal gland problems (carcinoid crisis):** During your treatment you may experience certain symptoms that are related to hormones released from your cancer. These symptoms may include flushing, diarrhea, difficulty breathing (bronchospasm), and low blood pressure (hypotension), and may occur during or within the 24 hours after your first LUTATHERA treatment. Your health care provider will monitor you closely. Speak with your health care provider if you experience any of these signs or symptoms.
- **Pregnancy warning:** Tell your health care provider if you are pregnant. LUTATHERA can harm your unborn baby. Females should use an effective method of birth control during treatment and for 7 months after the last dose of LUTATHERA. Males with female partners should use an effective method of birth control during treatment with LUTATHERA and for 4 months after the last dose.
- **Breastfeeding warning:** You should not breastfeed during treatment with LUTATHERA and for 2.5 months after your last dose of LUTATHERA.
- **Fertility problems:** Treatment with LUTATHERA may cause infertility. This is because radiation absorbed by your testes or ovaries over the treatment period falls within the range of exposure in which temporary or permanent infertility may occur.

What are the most common side effects of LUTATHERA?

The most common and most serious side effects of LUTATHERA include decreased blood cell counts, increased liver enzymes, vomiting, nausea, increased blood glucose, and decreased blood potassium levels.

Talk to your doctor if you experience any of these side effects. There are other possible side effects of LUTATHERA. For more information and to learn more about LUTATHERA, talk to your doctor or health care provider.

Adverse reactions observed in children aged 12 years and older were similar to those observed in adults treated with LUTATHERA.

What other medicines may interact with LUTATHERA?

Tell your health care provider if you are taking any other medications. You should stop taking your long-acting somatostatin analogue at least 4 weeks before LUTATHERA treatment. You may continue taking short-acting somatostatin analogues up to 24 hours before your LUTATHERA treatment.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see full Prescribing Information for LUTATHERA.

Helpful resources

Find these tools and more on LUTATHERA.com/resources to use throughout your treatment journey.



Care Team Contact Brochure

Keep your care team contacts organized here so you know who to contact if you have any questions.

Treatment Cards

Use these cards to keep track of important information about your LUTATHERA treatment.

Actor portrayal.

IMPORTANT SAFETY INFORMATION (continued)

- **Bone marrow problems (continued):** Speak with your health care provider if you experience any signs or symptoms of infection, fever, chills, dizziness, shortness of breath, or increased bleeding or bruising. Your health care provider may need to adjust or stop your treatment accordingly.

NOVARTIS

LUTATHERA®
(lutetium Lu 177 dotatate)
injection, for intravenous use

Novartis Pharmaceuticals Corporation
East Hanover, New Jersey 07936-1080

4/26 FA-11572987